Swiss All Share Index
16.940,47
PKT
+47,25
PKT
+0,28
%
Werbung
Analysen zu Swiss All Share Index-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.05.22 | ams-OSRAM Underweight | Barclays Capital | |
| 04.05.22 | ams-OSRAM Neutral | Credit Suisse Group | |
| 03.05.22 | ams-OSRAM Neutral | UBS AG | |
| 03.05.22 | ams-OSRAM Overweight | JP Morgan Chase & Co. | |
| 02.05.22 | Givaudan Neutral | Goldman Sachs Group Inc. | |
| 02.05.22 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.04.22 | UBS Sector Perform | RBC Capital Markets | |
| 28.04.22 | UBS Underweight | JP Morgan Chase & Co. | |
| 28.04.22 | UBS Hold | Deutsche Bank AG | |
| 28.04.22 | ABB (Asea Brown Boveri) Outperform | RBC Capital Markets | |
| 28.04.22 | UBS Underweight | Barclays Capital | |
| 28.04.22 | UBS Neutral | UBS AG | |
| 28.04.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.04.22 | Holcim Hold | Deutsche Bank AG | |
| 28.04.22 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 27.04.22 | Richemont Buy | HSBC | |
| 27.04.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 27.04.22 | UBS Buy | Goldman Sachs Group Inc. | |
| 27.04.22 | UBS Outperform | Credit Suisse Group | |
| 27.04.22 | Novartis Neutral | Credit Suisse Group | |
| 27.04.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.04.22 | UBS Buy | Deutsche Bank AG | |
| 27.04.22 | UBS Neutral | Goldman Sachs Group Inc. | |
| 27.04.22 | Novartis Neutral | UBS AG | |
| 27.04.22 | Novartis Sell | Deutsche Bank AG | |
| 27.04.22 | UBS Sector Perform | RBC Capital Markets | |
| 27.04.22 | UBS Outperform | RBC Capital Markets | |
| 27.04.22 | UBS Hold | Jefferies & Company Inc. | |
| 27.04.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 27.04.22 | UBS Underweight | Barclays Capital | |
| 27.04.22 | UBS Equal Weight | Barclays Capital | |
| 26.04.22 | DocMorris Buy | Jefferies & Company Inc. | |
| 26.04.22 | Novartis Neutral | UBS AG | |
| 26.04.22 | Roche Neutral | Credit Suisse Group | |
| 26.04.22 | Roche Buy | Deutsche Bank AG | |
| 26.04.22 | Roche Overweight | Barclays Capital | |
| 26.04.22 | Novartis Buy | Jefferies & Company Inc. | |
| 26.04.22 | UBS Buy | Jefferies & Company Inc. | |
| 26.04.22 | UBS Outperform | RBC Capital Markets | |
| 26.04.22 | Novartis Underweight | JP Morgan Chase & Co. |